15 July 1999
Source: http://www.access.gpo.gov/su_docs/aces/fr-cont.html

-------------------------------------------------------------------------

[Federal Register: July 15, 1999 (Volume 64, Number 135)]
[Notices]
[Page 38183-38184]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr15jy99-33]

=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Department of the Army


Availability for Non-Exclusive, Exclusive, or Partially Exclusive
Licensing of U.S. Patent Applications Concerning Dengue Vaccines

AGENCY: U.S. Army Medical Research and Materiel Command, DoD.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: In accordance with 37 CFR 404.6, and 404.7, announcement is
made of the availability for licensing of Provisional U.S. Patent
Applications, Serial Numbers 60/126,311 (filed March 26, 1999) and
entitled ``Live Attenuated Dengue-3 Vaccine''), 60/126,313 (filed March
26, 1999 and entitled ``Live Attenuated Multivalent Dengue

[[Page 38184]]

Vaccine''), 60/126,316 (filed March 26, 1999 and entitled ``Adaptation
of Virus to Vero and Other Vertebrate Cells''), 60/126,317 (filed March
26, 1999 and entitled ``Dengue-1 Virus Vaccine''), 60/126,318 (filed
March 26, 1999 and entitled ``Live Attenuated Dengue-4 Vaccine''), and
60/126,319 (filed March 26, 1999 and entitled ``Live Attenuated Dengue-
2 Vaccine''). These inventions have been assigned to the United States
Government as represented by the Secretary of the Army.

ADDRESSES: Commanding General, U.S. Army Medical Research and Materiel
Command, ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort
Detrick, Frederick, Maryland 21702-5012.

FOR FURTHER INFORMATION CONTACT: Mr. Charles Harris, Patent Attorney,
301-619-2065, or FAX 301-619-5034.

SUPPLEMENTARY INFORMATION: The inventions describe a novel strain of
dengue virus derived by empirical passage of the virus in primary dog
kidney cell cultures. Passage of these cells selected for modified
strains of dengue virus that are attenuated in humans. Human
inoculation has demonstrated that the strains are safe, cause minimal
side reactions, but result in infections that stimulate immune
responses to the virus. It is thought that this immunity will protect
the recipients from natural infection and diseases caused by the virus
strains. The invention of Provisional Application SN 60/126,316 relates
to the description of the use of Vero and other cell lines for the
production and manufacture of dengue vaccines.
Gregory D. Showalter,
Army Federal Register Liaison Officer.
[FR Doc. 99-18012 Filed 7-14-99; 8:45 am]
BILLING CODE 3710-08-M
